Cytori Therapeutics (CYTX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Cytori Reports Third Quarter 2015 Business and Financial Results
November 5, 2015 4:15 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) today announced its third quarter financial results and provided updates on its corporate activity and clinical development.
Third quarter 2015 net income allocable to common stockholders was $1.5 million, or a net loss of $5.8 million and $0.04 per share when excluding a non-cash charge of $7.3 million related to the change in fair value of warrant liabilities. Cytori continued to reduce its operating cash burn, spending approximately $6.1 million in the third quarter 2015. Cytori ended the second quarter of 2015 with $19 million of cash and cash equivalents.
... More
